The pharmacokinetics and safety of darapladib in subjects with severe renal impairment

• Published in: British journal of clinical pharmacology Vol. 80; no. 4; pp. 654 - 661
• Main Authors: He Magee, Mindy, Shaddinger, Bonnie, Collins, David, Siddiqi, Shabana, Soffer, Joseph
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Ltd 01.10.2015
• Subjects: Adolescent; Adult; Aged; atherosclerosis; Benzaldehydes - adverse effects; Benzaldehydes - blood; Benzaldehydes - pharmacokinetics; darapladib; Female; Humans; Male; Middle Aged; Oximes - adverse effects; Oximes - blood; Oximes - pharmacokinetics; Pharmacokinetics; phospholipase A2; Phospholipase A2 Inhibitors - adverse effects; Phospholipase A2 Inhibitors - blood; Phospholipase A2 Inhibitors - pharmacokinetics; renal impairment; Renal Insufficiency - metabolism; Young Adult; atherosclerosis; pharmacokinetics; darapladib; phospholipase A2; renal impairment

Aim Darapladib is a potent and reversible orally active inhibitor of lipoprotein‐associated phospholipase A2 (Lp‐PLA2). The aim of the study was to assess the effects of severe renal impairment on the pharmacokinetics and safety/tolerability of darapladib compared with normal renal function. Methods...